Payment overview · 2025
General Payments
$869.60
51 reported records · 11 companies
Healthcare provider profile · identity verified
Brian James Duff, MD
Allopathic & Osteopathic Physicians|Family Medicine · NIXA, MO · NPI 1447411145
Verified facts
What the public records show
CMS Open Payments records show Brian James Duff, MD received $869.60 in general payments during 2025 across 51 reported records.
PFIZER INC. accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $244.48 | 28.1% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $164.33 | 18.9% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.82 | 14.5% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $87.39 | 10.1% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $82.74 | 9.5% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $61.99 | 7.1% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $29.41 | 3.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.02 | 2.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.80 | 2.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.46 | 1.9% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $16.16 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $869.60 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $214.44 | 15 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $214.44 | 15 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $96.61 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $88.26 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $87.39 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $82.74 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.07 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $61.99 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.80 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.72 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $29.41 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.21 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| Axonics Normalized: axonics |
Device | Boston Scientific Corporation | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $11.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 13 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 228 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 203 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
63 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
203 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
228 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1073 | 299 |
| Lisinopril | Lisinopril | 733 | 190 |
| Amlodipine Besylate | Amlodipine Besylate | 731 | 191 |
| Losartan Potassium | Losartan Potassium | 560 | 150 |
| Gabapentin | Gabapentin | 557 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 557 | 143 |
| Tramadol Hcl | Tramadol Hcl | 435 | 76 |
| Omeprazole | Omeprazole | 408 | 108 |
| Tamsulosin Hcl | Tamsulosin Hcl | 396 | 105 |
| Metformin Hcl | Metformin Hcl | 334 | 95 |
| Alprazolam | Alprazolam | 312 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 303 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 281 | 83 |
| Furosemide | Furosemide | 270 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 258 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 85 |
| Trazodone Hcl | Trazodone Hcl | 255 | 68 |
| Lorazepam | Lorazepam | 254 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 249 | 52 |
| Eliquis | Apixaban | 228 | 47 |
| Simvastatin | Simvastatin | 225 | 65 |
| Potassium Chloride | Potassium Chloride | 214 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 214 | 30 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 208 | 189 |
| Ozempic | Semaglutide | 203 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 202 | 43 |
| Montelukast Sodium | Montelukast Sodium | 199 | 50 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 196 | 57 |
| Meloxicam | Meloxicam | 196 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 190 | 47 |
| Carvedilol | Carvedilol | 185 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 50 |
| Pregabalin | Pregabalin | 170 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 169 | 48 |
| Sertraline Hcl | Sertraline Hcl | 167 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 153 | 41 |
| Famotidine | Famotidine | 153 | 31 |
| Alendronate Sodium | Alendronate Sodium | 150 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 31 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 128 | 128 |
| Clonazepam | Clonazepam | 128 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 29 |
| Spironolactone | Spironolactone | 118 | 34 |
| Allopurinol | Allopurinol | 117 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 117 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 32 |
| Glimepiride | Glimepiride | 111 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 29 |
| Lovastatin | Lovastatin | 108 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 106 | 25 |
| Celecoxib | Celecoxib | 103 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 101 | 30 |
| Baclofen | Baclofen | 88 | 17 |
| Prednisone | Prednisone | 86 | 52 |
| Propranolol Hcl | Propranolol Hcl | 85 | 26 |
| Warfarin Sodium | Warfarin Sodium | 85 | suppressed |
| Bupropion Xl | Bupropion Hcl | 84 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 15 |
| Finasteride | Finasteride | 79 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 73 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 69 | 13 |
| Atenolol | Atenolol | 68 | 20 |
| Buspirone Hcl | Buspirone Hcl | 67 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 63 | 19 |
| Donepezil Hcl | Donepezil Hcl | 62 | 19 |
| Fenofibrate | Fenofibrate | 62 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 60 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 56 | 12 |
| Ibuprofen | Ibuprofen | 51 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 34 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Estradiol | Estradiol | 43 | suppressed |
| Glipizide | Glipizide | 42 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | 14 |
| Diazepam | Diazepam | 38 | 12 |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Naproxen | Naproxen | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 29 |
| Klor-Con M20 | Potassium Chloride | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Acyclovir | Acyclovir | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 16 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 32 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 32 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Irbesartan | Irbesartan | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Glyburide | Glyburide | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Ciclopirox | Ciclopirox | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Cartia Xt | Diltiazem Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 12 |
| Nystatin | Nystatin | 17 | 11 |
| Fluconazole | Fluconazole | 16 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Inderal La | Propranolol Hcl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Altoprev | Lovastatin | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $869.60 · 51 records | PFIZER INC. | ABRYSVO, Axonics, BREZTRI, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE, INSPIRE, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, UBRELVY, Veozah, Wegovy, XYOSTED, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error